Physician profile
Abigail Whitehead
NPI 1841975505
$894.69
in general payments reported to CMS, 2019-2025
15 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $147 · 2024: $355 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.04 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.81 | 2023-2025 | Trintellix, Iclusig |
| Exact Sciences Corporation | $51.16 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $49.94 | 2023-2024 | Farxiga |
| Amgen INC. | $46.60 | 2024-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $45.34 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.89 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $35.79 | 2023 | Mounjaro |
| Dexcom, INC. | $35.74 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $33.51 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $26.24 | 2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $21.41 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $15.59 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.06 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.